A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | MicrobiomeTrials
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-05-10Est. Completion: 2025-12-03
Enrollment target: 65 participants
Locations
Col Uni Med Center New York Presby, New York, New York, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center Uni of Te, Houston, Texas, United States
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States